Abbott Laboratories (NYSE: ABT) on Thursday announced financial results for the fourth quarter of 2024, reporting an increase in sales and adjusted profit.
Total reported sales increased 7.2 year-over-year to $10.9 billion in the December quarter, exceeding estimates. Organic sales for the underlying base business grew 10.1%.
Adjusted earnings moved up to $1.34 per share in Q4 from $1.19 per share in the year-ago quarter and matched Wall Street’s expectations. Unadjusted profit rose sharply to $9.23 billion or $5.27 per share in the fourth quarter from $1.60 billion or $0.91 per share in Q4 2023, reflecting a significant tax benefit.
(this story will be updated shortly with infographic)
The post Highlights of Abbott Laboratories (ABT) Q4 2024 results first appeared on AlphaStreet.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
